Gilead COO: Analysts’ sky-high hep C drug view ‘not unreasonable’

By Bill Berkrot NEW YORK (Reuters) – When Gilead Sciences Inc declined to project 2014 revenue for its high-profile new hepatitis C drug last week, its shares fell nearly 7 percent over the next two days. On Tuesday, Gilead President and Chief Operating Officer John Milligan again declined to predict sales of the medicine that won U.S. marketing approval in December.